Federico Innocenti


Affiliation: University of North Carolina
Country: USA


  1. Toffoli G, Sharma M, Marangon E, Posocco B, Gray E, Mai Q, et al. Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer. Clin Cancer Res. 2017;23:918-924 pubmed publisher
    ..The antitumor efficacy of these genotype-guided doses should be tested in future studies of patients with mCRC treated with FOLFIRI plus bevacizumab. Clin Cancer Res; 23(4); 918-24. ©2016 AACR. ..
  2. Innocenti F, Ramirez J, Obel J, Xiong J, Mirkov S, Chiu Y, et al. Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751. Pharmacogenet Genomics. 2013;23:374-81 pubmed publisher
    ..A-priori selection of candidate genes guided by in-vitro metabolic screening enhanced our ability to identify genetic determinants of interpatient pharmacokinetic variability. ..
  3. Crona D, Skol A, Leppänen V, Glubb D, Etheridge A, Hilliard E, et al. Genetic Variants of VEGFA and FLT4 Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib. Cancer Res. 2019;79:231-241 pubmed publisher
    ..SIGNIFICANCE: Clinical and mechanistic data identify germline genetic variants in VEGFA and FLT4 as markers of survival in patients with metastatic renal cell carcinoma. ..